ADMA (ADMA) director receives new RSU and stock option grants

Rhea-AI Filing Summary

ADMA Biologics director Jerrold B. Grossman received new equity awards. On February 9, 2026, he was granted 10,690 restricted stock units of common stock at $0, which vest in two equal installments over one year, subject to continued service.

He was also granted stock options for 17,730 shares of common stock at a $16.37 exercise price, with these options vesting in twelve equal monthly installments over one year. Following the grant, he directly beneficially owned 488,884 shares of common stock, including previously granted RSUs, and held additional indirect interests through an LLC, a trust, a foundation, and his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Jerrold B

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		10,690(1)	A	$0	488,884(2)	D
Common Stock								22,857	I	See footnote(3)
Common Stock								31,381	I	See footnote(4)
Common Stock								38,294	I	See footnote(5)
Common Stock								175	I	See footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.37	02/09/2026		A		17,730		(7)	02/09/2036	Common Stock	17,730	$0	17,730	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person.

3. These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.

4. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.

5. These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.

6. These shares are owned by the Reporting Person's wife.

7. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADMA director Jerrold Grossman report on February 9, 2026?

Jerrold Grossman reported receiving equity awards from ADMA Biologics, not open‑market trades. He was granted 10,690 restricted stock units and stock options for 17,730 shares, both tied to continued service and time‑based vesting schedules rather than immediate cash purchases or sales.

How many restricted stock units did ADMA’s Jerrold Grossman receive and how do they vest?

He received 10,690 restricted stock units of ADMA common stock at $0. These RSUs vest in two equal installments on the six‑ and twelve‑month anniversaries of the February 9, 2026 grant date, becoming fully vested after one year if he continues in service.

What stock options were granted to ADMA director Jerrold Grossman in this Form 4?

He was granted stock options covering 17,730 ADMA common shares with a $16.37 exercise price. The options vest in twelve equal monthly installments starting from the February 9, 2026 grant date, becoming fully vested after one year, subject to his continued service.

What is Jerrold Grossman’s direct ownership in ADMA common stock after the reported grants?

After the reported transaction, he directly beneficially owned 488,884 ADMA common shares, including RSUs described in the filing. This figure reflects both newly granted and previously outstanding equity awards credited to him as of the transaction date.

What indirect ADMA shareholdings are associated with Jerrold Grossman?

Indirect interests include shares held by Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife. The filing notes his roles with these entities, such as managing member, investment trustee, or president, which explain how these indirect holdings are structured.

Do the new ADMA equity awards to Jerrold Grossman involve any cash purchase or sale?

No cash purchase or sale is reported for these awards. The RSUs are granted at $0, and the stock options are granted at $0 with a $16.37 exercise price, reflecting compensatory grants rather than market transactions involving immediate cash consideration.